Bradley Merrill Thompson, a Member of the Firm in the Health Care and Life Sciences practice, in the Washington, DC, office, wrote an op-ed titled "Counting Our Blessings with the Office of Combination Products."
Following is an excerpt:
As reported in Seriously, What is Going On at the Office of Combination Products?, some in the medical device community have criticized the Office of Combination Products (OCP) at FDA. In particular, those critics have accused OCP, ironically, both of being weak because the office lacks independent authority and for overstepping its bounds. How is that even possible?
But it is that criticism which is out of bounds. Since its inception, OCP has served as an important resource to combination product manufacturers of all shapes and sizes.
